Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease

被引：0
作者：
Teddy Kosoglou
Walter K. Kraft
Bharath Kumar
Paul Statkevich
Fengjuan Xuan
Lei Ma
Lisa K. Jennings
James E. Schiller
Ronald B. Langdon
David L. Cutler
机构：
[1] Merck Sharp & Dohme Corp.,Department of Pharmacology and Experimental Therapeutics
[2] Thomas Jefferson University,Clinical Pharmacology, Merck Research Laboratories
[3] University of Tennessee Health Science Center,undefined
[4] Merck Sharp & Dohme Corp.,undefined
来源：
European Journal of Clinical Pharmacology | 2012年 / 68卷
关键词：
Vorapaxar; SCH 530348; PAR-1; Renal disease; Pharmacokinetics; Pharmacodynamics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1049 / 1056
页数：7
相关论文
共 50 条
[41]   Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment [J].
Luzelena Caro ;
Larissa Wenning ;
Hwa-Ping Feng ;
Zifang Guo ;
Lihong Du ;
Pratik Bhagunde ;
Christine Fandozzi ;
Deborah Panebianco ;
William L. Marshall ;
Joan R. Butterton ;
Marian Iwamoto ;
Wendy W. Yeh .
European Journal of Clinical Pharmacology, 2019, 75 :665-675
[42]   Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment [J].
Caro, Luzelena ;
Wenning, Larissa ;
Feng, Hwa-Ping ;
Guo, Zifang ;
Du, Lihong ;
Bhagunde, Pratik ;
Fandozzi, Christine ;
Panebianco, Deborah ;
Marshall, William L. ;
Butterton, Joan R. ;
Iwamoto, Marian ;
Yeh, Wendy W. .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 75 (05) :665-675
[43]   Pharmacokinetics and safety of iomeprol in healthy volunteers and in patients with renal impairment or end-stage renal disease requiring hemodialysis [J].
Lorusso, V ;
Taroni, P ;
Alvino, S ;
Spinazzi, A .
INVESTIGATIVE RADIOLOGY, 2001, 36 (06) :309-316
[44]   Pharmacokinetics of Treprostinil Diolamine in Subjects With End-Stage Renal Disease On or Off Dialysis [J].
Jenkins, Amanda ;
Wang-Smith, Laurene ;
Marbury, Thomas ;
Laliberte, Kevin .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2013, 61 (04) :272-276
[45]   Safety Outcomes of Apixaban Compared With Warfarin in Patients With End-Stage Renal Disease [J].
Sarratt, Stefanie C. ;
Nesbit, Ross ;
Moye, Robert .
ANNALS OF PHARMACOTHERAPY, 2017, 51 (06) :445-450
[46]   Implanted renal replacement for end-stage renal disease [J].
Roy, S. ;
Goldman, K. G. ;
Marchant, R. E. ;
Zydney, A. L. ;
Brown, D. L. ;
Fleischman, A. J. ;
Conlisk, A. T. ;
Desai, T. A. ;
Duffy, S. ;
Humes, H. D. ;
Fissell, W. H. .
PANMINERVA MEDICA, 2011, 53 (03) :155-166
[47]   Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis [J].
Parasrampuria, Dolly A. ;
Marbury, Thomas ;
Matsushima, Nobuko ;
Chen, Shuquan ;
Wickremasingha, Prachi K. ;
He, Ling ;
Dishy, Victor ;
Brown, Karen S. .
THROMBOSIS AND HAEMOSTASIS, 2015, 113 (04) :719-727
[48]   Effect of the Thrombin Receptor Antagonist (PAR-1) Vorapaxar on QT/QTc Interval in Healthy Volunteers: A Randomized, Placebo- and Positive-Controlled, Parallel Group Trial [J].
Kosoglou, Teddy ;
Hunt, Thomas L. ;
Xuan, Fengjuan ;
Kumar, Bharath ;
Statkevich, Paul ;
Hanson, Mary E. ;
Cutler, David L. .
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2014, 3 (01) :18-24
[49]   Pharmacokinetics of Enarodustat in Non-Japanese and Japanese Healthy Subjects and in Patients With End-Stage Renal Disease on Hemodialysis [J].
Pai, Sudhakar M. ;
Kambhampati, Siva Rama Prasad ;
Naruhashi, Shinya ;
Yamada, Hiroyuki .
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2023, 12 (07) :683-690
[50]   Pharmacokinetics of rosuvastatin in patients with end-stage kidney disease undergoing peritoneal dialysis [J].
Bologa, R. ;
Levine, D. ;
Parker, T. ;
Gordon, B. ;
Lanto, A. ;
Cheigh, J. ;
Stenzel, K. ;
Rubin, A. .
CLINICAL NEPHROLOGY, 2009, 72 (06) :437-441
12345